An in vivo strategy to counteract post-administration anticoagulant activity of azido-Warfarin
The interaction of long circulating drugs with biological molecules might trigger harmful side effects. Here, the authors design an anticoagulant compound that can be deactivatedin vivo using click chemistry, paving the way to the design of drugs with tunable in vivoproperties.
Guardado en:
Autores principales: | Sylvain Ursuegui, Marion Recher, Wojciech Krężel, Alain Wagner |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ebda2b9fe32443d9b94c7789c9666492 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Direct Oral Anticoagulant (DOAC) to Warfarin Transitions in a Pharmacist-led Anticoagulation Clinic
por: Ashley G. Woodhouse, et al.
Publicado: (2019) -
Direct Oral Anticoagulants Form Thrombus Different From Warfarin in a Microchip Flow Chamber System
por: Masanobu Ishii, et al.
Publicado: (2017) -
Direct Oral Anticoagulants versus Warfarin in Octogenarians with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Clara Bonanad, et al.
Publicado: (2021) -
Dorsal Spinal Chronic Subdural Hematoma Complicating Warfarin/Asprin Anticoagulation Therapy: A Case Report Study.
por: Emad Ghanem, et al.
Publicado: (2012) -
Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?
por: Dong Lin, et al.
Publicado: (2021)